Pascal Biosciences Inc. (PAS.V)
| Previous Close | 0.0200 |
| Open | 0.0200 |
| Bid | 0.0200 x N/A |
| Ask | 0.0250 x N/A |
| Day's Range | 0.0200 - 0.0200 |
| 52 Week Range | 0.0150 - 0.1100 |
| Volume | |
| Avg. Volume | 30,621 |
| Market Cap | 1.312M |
| Beta (5Y Monthly) | 1.39 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0160 |
| Earnings Date | Apr 23, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
UPDATE - InvestmentPitch Media Video Discusses Pascal Biosciences and its Non-Brokered Private Placement to Raise up to $900,000 with $0.10 Units – Video Available on Investmentpitch.com
VANCOUVER, British Columbia, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Pascal Biosciences (TSXV:PAS) (OTCPink:PSCBF) (FSE:6PB), a biotechnology company targeting innovative therapies for serious diseases, has announced a non-brokered private placement. The company is looking to raise gross proceeds of up to $900,000 from the placement of up to 9 million units priced at $0.10 per unit, with each unit consisting of 1 share and 1 warrant, with each warrant exercisable at $0.15 for 24 months, subject to an
- GlobeNewswire
InvestmentPitch Media Video Discusses Pascal Biosciences and its Award of a National Cancer Institute Grant for its Acute Lymphoblastic Leukemia Program – Video Available on Investmentpitch.com
Pascal Video Image InvestmentPitch Media Video Discusses Pascal Biosciences and its Award of a National Cancer Institute Grant for its Acute Lymphoblastic Leukemia Program – Video Available on Investmentpitch.com VANCOUVER, British Columbia, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Pascal Biosciences (TSXV:PAS) (OTCPink:PSCBF) (FSE:6PB), a biotechnology company targeting innovative therapies for serious diseases, including COVID-19, has been awarded a grant from the National Cancer Institute of the US
